机译:被开发为埃博拉病毒免疫保护剂的无岩藻糖单克隆抗体的增强效力
Mapp Biopharmaceutical, San Diego, CA 92121;
Department of Virology, US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;
Department of Virology, US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;
Mapp Biopharmaceutical, San Diego, CA 92121;
Mapp Biopharmaceutical, San Diego, CA 92121;
Mapp Biopharmaceutical, San Diego, CA 92121;
Mapp Biopharmaceutical, San Diego, CA 92121;
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215;
Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria;
Mapp Biopharmaceutical, San Diego, CA 92121;
Department of Virology, US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;
passive immunization; antibody glycosylation; antibody-dependent cellular cytotoxicity; antiviral;
机译:motavizumab的安全性,耐受性,药代动力学和免疫原性,motavizumab是一种人源化的增强效价单克隆抗体,用于预防高危儿童呼吸道合胞病毒感染。
机译:埃博拉GP特异性单克隆抗体可保护小鼠和豚鼠免受致命的埃博拉病毒感染
机译:单克隆抗体的肌内腺癌相关病毒介导的单克隆抗体的表达为小鼠的埃博拉病毒感染提供了100%的保护
机译:一种罕见的琥珀酰亚胺酰亚胺形成遗址,其导致治疗单克隆抗体的稳定性研究中的效力损失
机译:ELISA方法的开发,用于使用单克隆抗体检测和鉴定LASSA和埃博拉病毒。
机译:被开发为埃博拉病毒免疫保护剂的无岩藻糖单克隆抗体的增强效力
机译:被开发为埃博拉病毒免疫保护剂的无岩藻糖单克隆抗体的增强效力
机译:用植物来源的单克隆抗体延迟治疗埃博拉病毒感染为恒河猴提供保护。